{"DataElement":{"publicId":"3008778","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy Amyloidosis Autonomic Neuropathy Status Type","preferredDefinition":"A description of the best autonomic neuropathy response to therapy for amyloidosis.","longName":"2946463v1.0:3008773v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3008773","version":"1","preferredName":"Amyloidosis Autonomic Neuropathy Status Type","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._An inherited or acquired peripheral neuropathy affecting the autonomic nervous system. It results in disruption of the involuntary body functions. Inherited causes include Fabry disease and porphyrias. Acquired causes include diabetes, uremia, hepatic disorders, vitamin deficiencies, toxins, and drug toxicities._A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"3008773v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Autonomic neuropathy response","valueDescription":"Autonomic neuropathy response","ValueMeaning":{"publicId":"3193857","version":"1","preferredName":"Autonomic neuropathy response","longName":"3193857","preferredDefinition":"Resolution of symptomatic orthostatic hypotension","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D5F2496-5CD4-3EDC-E040-BB89AD43173D","latestVersionIndicator":"Yes","beginDate":"2011-02-28","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-02-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D5F2496-5CED-3EDC-E040-BB89AD43173D","beginDate":"2011-02-28","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-02-28","modifiedBy":"ONEDATA","dateModified":"2011-02-28","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"Progressive disease","ValueMeaning":{"publicId":"3193856","version":"1","preferredName":"Progressive disease","longName":"3193856","preferredDefinition":"Worsening of symptomatic orthostatic hypotension not attributable to medications or blood volume depletion","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D5F2496-5CB2-3EDC-E040-BB89AD43173D","latestVersionIndicator":"Yes","beginDate":"2011-02-28","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-02-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D5F2496-5CCA-3EDC-E040-BB89AD43173D","beginDate":"2011-02-28","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-02-28","modifiedBy":"ONEDATA","dateModified":"2011-02-28","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"Not Done","ValueMeaning":{"publicId":"3104692","version":"1","preferredName":"Not Done","longName":"3104692v1.00","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or not been completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"88084310-6796-6259-E040-BB89AD4311C3","latestVersionIndicator":"Yes","beginDate":"2010-06-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-02","modifiedBy":"RAGUNATHANU","dateModified":"2022-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"9D5F2496-5CF7-3EDC-E040-BB89AD43173D","beginDate":"2010-02-10","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-02-28","modifiedBy":"ONEDATA","dateModified":"2011-02-28","deletedIndicator":"No"},{"value":"Not evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"9D5F2496-5D01-3EDC-E040-BB89AD43173D","beginDate":"2010-02-10","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-02-28","modifiedBy":"ONEDATA","dateModified":"2011-02-28","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F50D9150-D782-88D9-E040-BB89AD431D5E","beginDate":"2014-03-20","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-20","modifiedBy":"ONEDATA","dateModified":"2014-03-20","deletedIndicator":"No"},{"value":"No response / stable disease","valueDescription":"No response/stable disease","ValueMeaning":{"publicId":"4241816","version":"1","preferredName":"No response/stable disease","longName":"4241816","preferredDefinition":"Does not meet criteria for autonomic neuropathy response nor progressive disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F50D9150-D760-88D9-E040-BB89AD431D5E","latestVersionIndicator":"Yes","beginDate":"2014-03-20","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"18BBC999-9C5C-120B-E050-BB89AD437EDA","beginDate":"2014-03-20","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-06-17","modifiedBy":"ONEDATA","dateModified":"2015-06-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3008772","version":"1","preferredName":"Amyloidosis Autonomic Neuropathy Status Type","preferredDefinition":"A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.:An inherited or acquired peripheral neuropathy affecting the autonomic nervous system. It results in disruption of the involuntary body functions. Inherited causes include Fabry disease and porphyrias. Acquired causes include diabetes, uremia, hepatic disorders, vitamin deficiencies, toxins, and drug toxicities.:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C2868:C27033:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Autonomic Neuropathy","conceptCode":"C27033","definition":"An inherited or acquired peripheral neuropathy affecting the autonomic nervous system. It results in disruption of the involuntary body functions. Inherited causes include Fabry disease and porphyrias. Acquired causes include diabetes, uremia, hepatic disorders, vitamin deficiencies, toxins, and drug toxicities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F3DC927-70F9-F435-E040-BB89AD436823","latestVersionIndicator":"Yes","beginDate":"2010-02-10","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-10","modifiedBy":"ONEDATA","dateModified":"2010-02-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F3DC927-710A-F435-E040-BB89AD436823","latestVersionIndicator":"Yes","beginDate":"2010-02-10","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-10","modifiedBy":"NYCHM","dateModified":"2017-04-05","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964910","version":"1","longName":"2117r1: Amyloidosis Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"PCDpost_amy_hema_organ_autonom_neuropath_best_resp","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What is the best outcome of t","type":"Preferred Question Text","description":"What is the best outcome of therapy for amyloidosis autonomic neuropathy?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:3008778","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis > AssessedResultRelationship > PerformedObservation > PerformedClinicalinterpretation.value = \"best result\" AND PerformedDiagnosis.value = \"autonomic neuropathy\"","url":null,"context":"NHLBI"},{"name":"Specify the best response of autonomic neuropathy to the HCT","type":"Alternate Question Text","description":"Specify the best response of autonomic neuropathy to the HCT","url":null,"context":"NHLBI"},{"name":"Specify the best response of autonomic neuropathy to the HCT","type":"Application Standard Question Text","description":"Specify the best response of autonomic neuropathy to the HCT","url":null,"context":"NHLBI"},{"name":"Specify the best response of autonomic neuropathy to the HSCT","type":"Alternate Question Text","description":"Specify the best response of autonomic neuropathy to the HSCT","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F3DC927-71B9-F435-E040-BB89AD436823","latestVersionIndicator":"Yes","beginDate":"2010-02-10","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-10","modifiedBy":"KUMMEROA","dateModified":"2021-06-17","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}